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Trabecular meshworkThe purpose of this study was to determine how dexamethasone (DEX) regulates the expression and activity of
αvβ3 integrin. FACS analysis showed that DEX treatment induced expression of an activated αvβ3 integrin. Its
expression remained high as long as DEX was present and continued following DEX removal. FACS analysis
showed that the upregulation of αvβ3 integrin was the result of an increase in the expression of the β3 integrin
subunit. By real time qPCR, DEX treatment induced a 6.2-fold increase (p b 0.04) in β3 integrin mRNA by day 2
compared to control and remained elevated for 6 days of treatment and then an additional 10 days once the
DEX was removed. The increase in β3 integrin mRNA levels required only 1 day of DEX treatment to increase
levels for 4 days in the absence of DEX. In contrast, DEX did not alter β1 integrin mRNA or protein levels. The
DEX-induced upregulation of β3 integrin mRNA was partly due to an increase in its half-life to 60.7 h from
22.5 h in control cultures (p b 0.05) and could be inhibited by RU486 and cycloheximide, suggesting that DEX-
induced de novo protein synthesis of an activation factor was needed. The calcineurin inhibitors cyclosporin A
(CsA) and FK506 inhibited the DEX induced increase in β3 integrin mRNA. In summary, the DEX-induced in-
crease inβ3 integrin is a secondary glucocorticoid response that results in prolonged expression ofαvβ3 integrin
and the upregulation of the β3 integrin subunit through the calcineurin/NFAT pathway.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The αvβ3 integrin has been shown to be involved in the pathogen-
esis of a number of diseases including cancer, diabetes and osteoporosis
[1–6].More recently,αvβ3 integrin has been implicated as having a role
in steroid-induced glaucoma (SIG) [7–9]. SIG results from the long term
use of glucocorticoids (GCs) such as dexamethasone (DEX), most com-
monly through topical ocular application. About 30–40% of the normal
population exhibit elevated intraocular pressure (IOP) when treated
with GCs [10,11] with about 6% of these patients developing SIG. The
cause of this increase in IOP is believed to be a restriction in the move-
ment of aqueous humor through the trabecular meshwork (TM) of the
anterior segment of the eye.
A number of cytoskeletal events known to be regulated by integrins
have been implicated in glaucoma [12,13] including changes in contractil-
ity and a reorganization of the actin cytoskeleton into a unique structure
of cross linked actin networks called CLANs. CLANs are believed to alter
the contractile properties of TM cells bymaking themmore rigid and un-
able to respond to pressure changes in the eye [14]. They are observed inedical School, Department of
USA. Tel.: +1 608 262 4626;
ights reserved.higher frequency in glaucomatous and DEX-treated tissues [15] and DEX-
treated TM cell cultures [7,16]. In TM cell cultures, these networks can be
formed by the activation of an αvβ3 integrin/Src/Trio/Rac1 signaling
pathway [7–9] that may involve CD47 and requires crosstalk with a β1
integrin/Src/PI-3 kinase pathway. Inhibition of this pathway impairs
CLAN formation inDEX-treated cells suggesting thatαvβ3 integrin signal-
ingmay be responsible for some of the cellular changes observed in glau-
coma. Recent work supports this idea and shows that DEX increases the
expression of αvβ3 integrin in cells from the TM [7].
Despite the preponderance of studies implicating αvβ3 integrin in
disease processes we know very little about how the expression of
αvβ3 integrin is regulated. In bone marrow macrophages, IL-4 and to a
lesser extent IL-6, GM-CSF and TNFα, increase β3 integrin mRNA [17].
During angiogenesis, the Foxc1 and Foxc2 transcription factors has been
shown to regulate expression of the β3 integrin subunit in endothelial
cells via Forkhead-binding elements in the promoter region of the β3
integrin subunit [18,19]. In osteoblasts, β3 integrin expression is tran-
siently increased by DEX [20]. Studies show that expression of the β3
integrin subunit in osteoclasts is regulated by calcineurin and the tran-
scription factor NFATc1 [21,22]. The NFAT family of transcription factors
is activated through dephosphorylation by calcineurin. Calcineurin is a
ubiquitously expressed serine/threonine phosphatase that is activated
by Ca2+ ion and calmodulin binding. To date, calcineurin is the only
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tial for the activation of genes by NFATs.
In this study we used human trabecular meshwork cells, which are
specialized smoothmuscle-like cells in the eye that regulate the contrac-
tile properties of the anterior segment of the eye, to study how DEX reg-
ulates αvβ3 integrin expression. Our studies show that DEX increased
transcription of β3 integrin mRNA through a secondary glucocorticoid
response mechanism and required de novo protein synthesis. This in-
crease was sensitive to the immunosuppressive drugs cyclosporin A
(CsA) and FK506 indicating that calcineurin may be involved. Further-
more, we show that the increased transcription of β3 integrin mRNA
resulted in increased protein expression of the β3 integrin subunit that
persisted even after removal of DEX and that the αvβ3 integrin was in
an active conformation. These results suggest that induction of β3
integrin by DEX occurs at both the transcriptional and protein levels
andmay result in the dysregulation of an activatedαvβ3 integrin signal-
ing pathway that can lead to the cytoskeleton changes (i.e., CLANs) ob-
served in glaucoma. Understanding how DEX affects TM cells in the
eye is important since many systemic steroid treatments can lead to in-
creases in intraocular pressure and glaucoma.
2. Materials and methods
2.1. Materials
For western blotting, the primary antibodies used were: β3 integrin
mAb (EP2417Y, Abcam; 1:500), β1 integrin mAb (HB1.1, Millipore;
1:1000), FKBP51 (also known as FKBP5; 1:1000) pAb (Sigma-Aldrich)
and succinate dehydrogenase complex, subunit A (SDHA) mAb (2E3,
Abcam; 1:2000). Secondary antibodies used were goat anti-mouse or
anti-rabbit HRP conjugated Ab (Santa Cruz; 1:5000). Antibodies used
for FACS were: mouse IgG1 (BD Biosciences; 1:100), αvβ3 integrin
mAb (LM609, Millipore; 1:100), an activated β3 integrin mAb (CRC54,
Abcam; 1:100) and goat anti-mouse Alexa 488 conjugated Ab (Life
Technologies; 1:400). All inhibitors were obtained from Sigma-
Aldrich, Co.
2.2. Cell culture
TheN27TM-2 cell strain of human trabecularmeshwork (HTM) cells
were isolated from cadaver eyes of a 27-year old donor and cultured as
previously described [24] and used between passages 7–8. One week
after reaching conﬂuency, cells were treated with either 500 nM DEX
or 0.1% ethanol (EtOH; vehicle control). In some experiments, cells
were incubated with the RNA polymerase II inhibitor actinomycin D
(5 μg/ml). In other experiments, the glucocorticoid inhibitor RU486
(mifepristone; 2.5, 10 or 25 μg/ml), cycloheximide (25 μg/ml) or CsA
or FK506 (1 or 10 μM) was added 1 h prior to the addition of DEX or
EtOH and incubated for 2days.
2.3. Cell spreading assay
The cell spreading assay was done as previously described [7]. Brief-
ly, cells were spread for 1.5h on coverslips precoated with 20nM ﬁbro-
nectin and co-labeled with anti-αvβ3 integrin mAb and Alexa 488
conjugated phalloidin (Life Technologies) as described [9]. Images
were captured with an Axioplan 2 epiﬂuorescence microscope (Carl
Zeiss, Inc.) equippedwith anAxiocamHRmdigital camera usingAxioVi-
sion image acquisition software.
2.4. Immunoblotting
HTM cells were washed and lysed with lysis buffer (25mM Hepes,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM NaF, 1% NP-40, 0.25%
deoxycholate, HALT phosphatase inhibitor cocktail and HALT protease
inhibitor cocktail (Thermo Fisher Scientiﬁc, Inc.)). The cellular debrisin the cell lysate was removed by centrifugation at 10,000 ×g. A
bicinchoninic acid (BCA) assay (Pierce) was done to determine protein
concentration and the lysate (10μg) was separated on a 10% SDS-PAGE
and transferred to Immobilon-P (Millipore Corp.). The membrane was
blocked in 3% bovine serum albumin (BSA)/tris buffered saline (TBS)
or 5% milk/TBS (FKBP51 pAb) overnight at 4 °C and incubated with the
primary antibody in 1% BSA/TBS/0.1% Tween-20 or 5% milk/TBS/0.1%
Tween-20 for 1 h. Membranes were washed with TBS/0.1% Tween-20
and incubated for 1 h with horseradish peroxidase-conjugated goat
anti-rabbit or anti-mouse IgG. Bound antibody was detected with the
ECL Plus western blotting detection kit (Amersham Biosciences).
2.5. Flow cytometry
HTM cells treated with DEX or EtOHwere lifted from the plate with
Cell Dissociation Buffer (Sigma), washed with ice cold PBS and blocked
for 30min on ice with 2% BSA in PBS (blocking buffer). Cells were la-
beled with the primary antibodies for 1 h on ice in blocking buffer and
then incubated on ice for 30 min with the secondary antibody. Cells
were washed then resuspended in 1% paraformaldehyde in PBS. Flow
cytometry was done with a FACSCalibur (BD Biosciences) using FlowJo
software (Tree Star, Inc.) for analysis.
2.6. RNA isolation, reverse transcription and real-time (RT)-qPCR
Total RNA was isolated using the QIAshredder and RNeasy Plus
Mini Kits (Qiagen Inc.) and RNA concentration was determined using
a NanoDrop spectrophotometer. Total RNA (1 μg) was reverse tran-
scribed and RT-qPCR experiments using the synthesized cDNA were
performed as previously described [25]. Data were normalized to no
treatment and fold change compared to the β1 integrin housekeeping
gene was determined according to Pfafﬂ [26]. Primer pairs used were:
β1 integrin forward 5′-GTGGAGAATCCAGAGTGTCCCA-3′ and reverse
5′-GACCACAGTTGTTACGG-3′, β3 integrin forward 5′-GTGACCTGAAGG
AGAATCTGC-3′ and reverse 5′-TTCTTCGAATCATCTGGCC-3′, and FKBP51
forward 5′-CTCCCTAAAATTCCCTCGAATGC-3′ and reverse 5′-CCCTCTC
CTTTCCGTTTGGTT-3′.
2.7. Rate of RNA synthesis
Nascent RNA synthesis was determined using the Click-iT® Nascent
RNA Capture Kit (Life Technologies). Cells were treated with DEX or
EtOH for 2 days after which cells were labeled by incubation with
0.1mM 5-ethynyl uridine (EU) for 1 h in the presence of DEX or EtOH.
Cells were collected and the RNAwas isolated as described above. EU la-
beled RNA (1 μg total RNA) was then biotinylated and isolated using
Dynabeads® MyOne™ Streptavidin T1 magnetic beads according to
the manufacturer's instructions. RT-qPCR was performed as above
using primers for β3 integrin.
2.8. Data analysis
Data are presented as mean ± S.E.M. Statistical comparisons were
done using the Student t-test and a p valueb0.05was considered signif-
icant. Relative quantiﬁcation of the RT-qPCR data was performed
according to Pfafﬂ [26], using β1 integrin for normalization.
3. Results
3.1. DEX increases β3 integrin protein and mRNA levels
Fig. 1 shows that treating HTM cells with DEX increases the level of
αvβ3 integrin in focal adhesions (Fig. 1A vs. C). When stained with
phalloidin, a subset of the cells incubated with DEX also exhibited the
distinctive geodesic dome actin structure called CLANs thought to be in-
volved in glaucoma and caused byαvβ3 integrin signaling (Fig. 1B vs. D).
Fig. 1. Localization ofαvβ3 integrin in DEX and EtOH treated HTM cells. HTM cells treatedwith EtOH (A, B) or DEX (C, D) for 4days were spread on ﬁbronectin-coated coverslips for 1.5h
prior to ﬁxation. The cells were labeled with mAb LM609 against αvβ3 integrin (A, C) and phalloidin (B, D). Asterisks indicate areas enlarged in the insets; arrowheads indicate αvβ3
integrin-positive adhesions; arrows indicate part of a CLAN. Scale bar=20 μm.
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Fig. 2.DEX inducedβ3 integrin expression and activation. (A)HTM cellswere treatedwith
DEX or EtOH for 6days and cell lysates were analyzed for levels of β3 integrin, β1 integrin
and FKBP51. SDHA was included as a loading control. Blots are representative of 3 biolog-
ical replicates. (B) Cells were treatedwith DEX or EtOH for 6days. FACS analysis was done
using themAb LM609 againstαvβ3 integrin (left) or mAb CRC54 which detects activated
αvβ3 integrin (right). The fold change in geometric mean of DEX vs. EtOH is indicated the
panels for each antibody. Data representative of 2 biological replicates.
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HTM cells that leads to CLAN formation, western blot analysis was car-
ried out to detect changes in αvβ3 integrin expression over 6 days of
DEX treatment. This prolonged treatment was chosen in order to corre-
spond with the time frame needed to observe CLAN formation in vitro
[27] and the time course of patient treatment. As shown in Fig. 2A,
DEX induced a time dependent increase in the expression of the β3
integrin subunit starting 2 days after initiation of DEX treatment. By
day 5, the β3 integrin subunit level appeared to plateau. This increase
was not seen in the EtOH treated controls. Rather, β3 integrin levels ap-
pear to diminish the longer the EtOH treated cells were in culture
(Fig. 2A). The DEX-induced increase was unique to the β3 integrin sub-
unit as no changes were observed in β1 integrin levels. This upregula-
tion of expression was not limited to this cell strain and was observed
in three other HTM cell strains (data not shown). As a positive control
we also examined the levels of the FK506-binding protein FKBP51,
which is known to be induced by DEX in several cell types [28,29], in-
cluding TM cells [30]. As expected, FKBP51 also showed a DEX induced
increase in expression. However, this increase occurred after one day of
treatment compared to the 2days needed to increase β3 integrin. FACS
analysis veriﬁed the western blot analysis and showed that DEX treat-
ment increased the expression of β3 integrin at the cell surface 2.4
fold compared to EtOH (Fig. 2B). Although αvβ3 integrin had an active
conformation in both DEX-treated and ETOH-treated cells, as deter-
mined with the CRC54 mAb that detects activated αvβ3 integrin
(Fig. 2B, right panel), the level of activated αvβ3 integrin was ~2 fold
greater in the DEX-treated cells compared to the EtOH-treated cells. In
contrast, the level of the αv integrin subunit was not changed by DEX,
as determined by FACS (data not shown).
Using RT-qPCR, we found that DEX increased the expression of β3
integrin mRNA by 6.2 fold (pb0.04) after 2days of DEX treatment com-
pared to the EtOH controls. The mRNA levels remained elevated
throughout the 6 day treatment (Fig. 3A). In contrast, β1 integrin
mRNA was unaffected by DEX (data not shown) and therefore was
used as a housekeeping gene to control for normalization. As expected,
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Fig. 4. Elevated levels of β3 integrin persists following the removal of DEX. (A) Cells were
treatedwith DEX or EtOH for 6days after which cells were incubatedwithmedia alone for
7 days (upper panels) or 14 days (lower panels). FACS analysis was done with the mAb
LM609 against αvβ3 integrin (left) or mAb CRC54 which detects activated αvβ3 integrin
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was collected every other day after DEX or EtOH removal and analyzed for the expression
of β3 integrin and FKBP51. SDHAwas included as a loading control. Blots representative of
2 biological replicates. (C) Cells were collected every other day after DEX or EtOH removal
and total RNA was analyzed by RT-qPCR. Ct values were corrected for primer efﬁciency
and compared to cellswith no treatment as describedby Pfafﬂ [26]. Datawas then normal-
ized to the β1 integrin housekeeping gene. DEX signiﬁcantly different from equivalent
EtOH control, *p b 0.05. n=3 biological replicates.
3309J.A. Faralli et al. / Biochimica et Biophysica Acta 1833 (2013) 3306–3313FKBP51 mRNA levels also increased by 7.3 fold (pb0.04) and remained
elevated throughout the treatment (Fig. 3B). The increase in FKBP51
mRNA levels appeared after only 1 day of DEX treatment compared to
2days for β3 integrin mRNA.
To determine if 2 days of DEX treatment was needed to increase β3
integrin mRNA levels, cultures were treated with DEX for 1 day only.
As shown in Fig. 3C, β3 integrin mRNA levels still increased on day 2
even though DEX was not present on the second day. However, in the
absence of any additional DEX, the mRNA levels started to decrease
and by day 5 the levels of β3 integrin mRNA returned to baseline.
Since some individuals treatedwith glucocorticoids go on to develop
glaucoma even after glucocorticoid treatment has stopped, we asked
what happens to αvβ3 integrin expression once DEX is removed. FACS
analysis (Fig. 4A, left panels) showed that β3 integrin expression
remained 1.59 fold higher 14 days after removal of DEX compared to
EtOH. Interestingly, there was still an elevation (~1.75 fold) in the
level of activated αvβ3 integrin in the DEX-treated cells compared to
the EtOH treated cells 7 days after the removal of the DEX (Fig. 4A,right panels). By day 14, little of the αvβ3 integrin in the DEX-treated
cells was activated, although protein expression was still upregulated.
Western blot analysis of lysate from cells treated with DEX followed
by DEX removal veriﬁed the FACS analysis and showed that total β3
3310 J.A. Faralli et al. / Biochimica et Biophysica Acta 1833 (2013) 3306–3313integrin expressionwas still elevated 12days after DEX removal (Fig. 4B).
The increase in β3 integrin levels coincided with its mRNA levels which
remained elevated for up to 10days after removal of DEX from the medi-
um (Fig. 4C). In contrast, FKBP51 protein levels returned to EtOH control
levels 8days after removing DEX. Similar results were seen at the mRNA
level for FKBP51.
3.2. β3 integrin mRNA half-life and synthesis rate increase with DEX
We next used actinomycin D to determine if the accumulation of β3
integrinmRNA could also be attributed to an increase inmRNAhalf-life.
Cells were treated for two days with DEX or EtOH after which a ﬁnal
concentration of 5μg/ml actinomycin D was added to fresh media con-
taining DEX and EtOH for 4, 8, 12 or 24h. Fig. 5A shows that in the pres-
ence of actinomycin D there was no signiﬁcant decrease in the β3
integrin mRNA compared to the zero time at 4, 8 or 12h. However, β3
integrin mRNA levels were signiﬁcantly different from time zero at
24 h (p b 0.025). In contrast, there was a signiﬁcant decrease in the
level of β3 integrin mRNA in the EtOH treated controls over the entire
24 h. The half-life in DEX and EtOH treated cells was 60.7 and 22.5 h
respectively (pb 0.05 overall). This suggests that the half-life of the β3
integrin mRNA was increased in the presence of DEX. In addition to
mRNA half-life, DEX also increased β3 integrin mRNA synthesis. Cells
treatedwithDEX or EtOH for 2dayswere labeledwith 5-ethynyl uridine
(EU) for 1 h to detect nascent RNA. Fig. 5B shows a 5.9 fold increase in
nascent β3 integrin mRNA compared to EtOH treated cells (pb0.025).0
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**p b 0.025. n=4 biological replicates (A) or 3 biological replicates (B).3.3. The increase in β3 integrin mRNA requires glucocorticoid receptor
signaling
The delay in β3 integrinmRNA induction by DEX suggests that this is
a secondary glucocorticoid response and that another factor induced by
DEX is needed for the increase seen in β3 integrinmRNA levels. To test if
the DEX-induced increase in αvβ3 integrin is mediated through gluco-
corticoid receptor (GR) signaling, cultures were treated with the GR an-
tagonist RU486. The RU486-GR complex interacts with DNA at a much
lower afﬁnity than that of the dexamethasone–GR complex and can act
as an agonist when other transcriptional coactivators are activated or
in speciﬁc cells lines [31–33]. For this experiment, RU486 was added 1h
prior to the addition of DEX or EtOH, to determine if a DEX-induced factor
was responsible for the increase in β3 integrin mRNA. In the absence of
RU486, DEX increased β3 integrin mRNA by 5.4 fold on the second day
of treatment (p b 0.001; Fig. 6A). Preincubation with RU486 eliminated
this increase in β3 integrin mRNA, suggesting that the increase was due
to a glucocorticoid signaling event. RU486 by itself was able to increase
β3 integrin mRNA in the EtOH controls, but not to the same extent as
DEX alone.
3.4. DEX induces β3 integrin through a secondary glucocorticoid response
mechanism
To demonstrate that this is a secondary glucocorticoid response and
required de novo protein synthesis expression for induction [34],
cultures were pretreated with cycloheximide. As shown in Fig. 6B,
treatment with cycloheximide caused a signiﬁcant decrease in the
level of β3 integrin mRNA induction observed at day 2 (p b 0.05). In
contrast, pre-treatment with cycloheximide had no inhibitory effect
on the DEX-induced increase in FKBP51 mRNA levels observed after
one day of DEX treatment (Fig. 6C). These results indicate that tran-
scription of the FKBP51 mRNA was directly induced by DEX whereas
transcription of the β3 integrin mRNA required translation of a DEX-
induced protein.
3.5. Calcineurin regulates β3 integrin
To understand the mechanisms by which DEX induced β3 integrin
mRNA expression we treated the cells with CsA and FK506. CsA and
FK506 are immunosuppressants that inhibit calcineurin, a phosphatase
that activates the NFAT family of transcription factors [23]. NFATc1 had
previously been shown to directly induce β3 integrin expression in os-
teoclasts [21]. FK506 has also been shown to suppress endogenous ex-
pression of NFATc1 [35]. Figs. 7A and B show that in cells pretreated
with either CsA or FK506, the DEX-induced increase in β3 integrin
mRNA was signiﬁcantly inhibited, suggesting that calcineurin may
play a role in regulating β3 integrin mRNA levels. Only CsA, however,
completely inhibited the increase in β3 integrin mRNA back to the
control level. This was not completely unexpected since several studies
have shown that these compounds exhibit different efﬁciencies at
inhibiting calcineurin [36,37] which may be due to the levels of their
respective target immunophilins.
4. Discussion
In this paper we demonstrate that the upregulation of β3 integrin
mRNA and protein levels by DEX was a secondary glucocorticoid re-
sponse that was regulated by calcineurin. This novel induction of β3
integrin expression appeared to be triggered by a classic GR-mediated
pathway since it could be inhibited by RU486. The increase in β3
integrin expression was due both to an increase in the half-life of
the β3 integrin mRNA as well as an increase in transcription. It resulted
in an expression of the β3 integrin subunit that persisted for days
even after the removal of DEX. Thus, DEX appears to speciﬁcally trig-
ger a long-term dysregulation of αvβ3 integrin signaling in trabecular
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CHX (B, C) prior to the addition of DEX or EtOH for 2 days (A, B) or 1 day (C). Fresh
media containing inhibitor and DEX or EtOH were added after 1 day (A, B). Ct values
were corrected for primer efﬁciency and compared to cells with no treatment as described
by Pfafﬂ [26]. Data were normalized to the β1 integrin housekeeping gene. Signiﬁcantly
different as indicated with brackets, *p b 0.05, ****p b 0.001. n= 3 biological replicates.
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Fig. 7. CsA and FK506 prevented the induction of β3 integrin mRNA by DEX. RT-qPCRwas
performed on HTM cells pretreated for 1 h with 1 or 10 μM CsA (A) or FK506 (B) prior to
the addition of DEX or EtOH for 2days. Fresh media containing inhibitor and DEX or EtOH
were added after 1 day. Ct values were corrected for primer efﬁciency and compared to
cellswith no treatment as describedby Pfafﬂ [26]. Datawerenormalized to theβ1 integrin
housekeeping gene. Signiﬁcantly different from DEX alone (no trt), *p b 0.05, **p b 0.025,
***p b 0.02. n=4 biological replicates (A, B) or 3 biological replicates (C).
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ed with glaucoma.
The DEX-induced upregulation of β3 integrin in HTM cells differed
from that previously reported in osteoblasts [20]. In those studies, β3
integrin was transiently expressed. In comparison, the upregulation of
β3 integrin persisted in HTM cells for 2 weeks even after the removal
of DEX. Themost likely explanation for this difference is that the upreg-
ulation of β3 integrin mRNA in osteoblasts involved speciﬁc palindrom-
ic sequences called glucocorticoid response elements (GREs) in the 5′
region of the β3 integrin promoter, suggesting a direct interaction be-
tween the GR and the GREs in the promoter. In contrast, this interaction
with the GREs did not appear to function in HTM cells, since the DEX-
induced upregulation of the β3 integrin subunit could be inhibitedwith cycloheximide, indicating the need for factor(s) to be synthesized
prior to the upregulation of the β3 subunit.
This DEX induced increase in β3 integrin mRNA levels may be
unique to HTM cells and is similar to that observed for the glucocorti-
coid response protein called myocilin [38,39]. Myocilin is a secreted
glycoprotein that is mutated in some juvenile open-angle glaucomas
[40–42]. Like the β3 integrin gene, myocilin also contains GREs and
the upregulation of its expression is also due to a secondary glucocorti-
coid response [38,39]. Why the GREs in myocilin and the β3 integrin
subunit are not utilized by the GR is not clear. There are a number of
factors which are responsible for mediating the interactions between
the GREs and the GR [43] including the multi-subunit complexes that
remodel chromatin, target the initiation sites and stabilize the RNA po-
lymerase II machinery.
It is presently unclear which factor(s) are involved in the upregula-
tion of β3 integrin. One possible mechanism may be that the GR is
exerting its effect through an indirect non-DNA binding mechanism
termed transrepression [44]. In this mechanism, transcriptional modu-
lation of the β3 integrin subunit could be achieved by cross-talk be-
tween the GR and other transcription factors such as NF-кB, AP-1 and
members of the STAT family. However, because it took 2 days to see
the upregulation and it required de novo protein synthesis, we tend to
favor the idea that DEX induced the expression of a soluble factor
which in turn activated calcineurin. In support of this idea, recent prote-
omic studies have shown that phosphatidylinositide 3-kinase (PI-3K)
and protein kinase C (PKC), both of which modulate calcineurin signal-
ing [23], are upregulated inHTMcells in response to DEX [25]. It was not
surprising that calcineurin was involved. Previous studies have shown
that the regulation of β3 integrin subunit involves NFATc1 [21,45]
which is a well established target of calcineurin [23]. Interestingly, in
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after one day of treatment with RANKL, a factor that induces osteoclast
formation, and detected in the nucleus after 2days of treatment [46,47].
Whether NFATc1 is upregulated by DEX in TM cells is unknown.
Calcineurin, has been shown to regulate the organization of the cyto-
skeleton. The involvement of calcineurin ﬁts with the observations that
in HTM cell cultures and in anterior segments, DEX induces the reorga-
nization of the actin cytoskeleton into CLANs [7,16]. This unique actin
structure is thought to make the cells more rigid so they cannot change
shape in response to pressure changes. This, in turn, causes the TM to
become more rigid which could restrict the outﬂow of aqueous humor
from the eye [14,48].
Interestingly, the DEX treatment also increased the stability of theβ3
integrin mRNA. The regulation of mRNA stability is a powerful mecha-
nism to alter long term gene expression and has been shown to be con-
trolled by hypoxia, inﬂammation, cancer and aging [49]. In terms of
steroid induced glaucoma or primary open angle glaucoma, this en-
hanced mRNA stability could have large implications especially since
the elevated levels of β3 integrin subunit at the cell surface also
appeared to bemore stable andmore of theαvβ3 integrinwas in the ac-
tivated state. At the present time, however, it is not possible to say
whether the increased mRNA expression was due to an increase in
mRNA stability or in transcription. This supports previous work from
our laboratory which showed that in the presence of DEX, CLAN forma-
tion is associated with a change in the conformation of αvβ3 integrin
that results in integrin activation. In the absence of DEX, CLANs can be
formed simply by activating αvβ3 integrin using either the AP-5 anti-
body or the thrombospondin peptide 4N1K [8]. Thus, a DEX induced
increase in β3 integrin expression and activation could explain the in-
creased frequency of CLAN formation observed in glaucomatous and
DEX-treated anterior segments.
In summary, this study suggests that some of the long term effects
normally attributed to SIG could be due to the indirect activation of
calcineurin that results in a prolonged dysregulation of αvβ3 integrin
signaling. Clearly additional studies looking at the other transcriptional
factors responsible for the secondary glucocorticoid response and their
role in the expression of proteins such as myocilin are warranted, since
it may provide insight on how to prevent undesirable steroid induced
side effects in the treatment of eye diseases.
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